



## → Nazia J. Khan

### Associate

2099 Pennsylvania Avenue, N.W.  
Suite 100  
Washington, DC 20006-6801

T: +1.202.747.2651

[nkhan@sheppardmullin.com](mailto:nkhan@sheppardmullin.com)

Nazia Khan is an associate in the Corporate Practice Group in the firm's New York and Washington D.C. offices and Co-Chair of the firm's Canada Desk Team which specializes in providing comprehensive cross-border legal services to Canadian-based clients across a broad spectrum of industries.

### Areas of Practice

Ms. Khan's practice focuses on corporate finance and securities laws. Ms. Khan represents underwriters and issuers in various industries including artificial intelligence, life sciences, healthcare, oil and gas, mining, technology, cannabis, food and beverage, transportation and REITs in capital markets transactions. Her experience includes leading both underwriters and issuers in public and private corporate finance transactions, including, but not limited to, initial public offerings, shelf registrations, registered direct transactions, private investments in public equity (PIPEs), private placements, secondary market purchases and other securities offerings. In addition, Ms. Khan's experience includes initial public offerings of SPACs as well as de-SPAC transactions and public company mergers and acquisitions, including reverse mergers.

Ms. Khan also has experience with U.S. cross-border corporate law matters, including cross-border securities matters. She leads foreign issuers and investment banks in a broad range of public and private financings, including, but not limited to, financings under the U.S.-Canada Multijurisdictional Disclosure System (MJDS) and U.S.-foreign private placements including Rule 144A and Regulation S offerings.

Ms. Khan also counsels U.S. and foreign issuers in connection with corporate governance matters including reporting obligations under the Exchange Act, New York Stock Exchange (NYSE), the Nasdaq Stock Market (Nasdaq), Cboe and FINRA. Furthermore, she assists foreign issuers with securities quoted on the OTCQX and OTCQB with Principal American Liaison (PAL) related matters.

Nazia has been recognized by Legal 500 as a leading attorney recommended in the Life Sciences sector for 2025 and selected a New York Metro Rising Stars, *Super Lawyers*, from 2017 through 2023, Ones to Watch – Corporate Law, *Best Lawyers*, 2021 and 2022 and *Who's Who in America*, 2019.

### Honors

Best Lawyers: Ones to Watch, *Best Lawyers*, 2026

New York Metro Rising Stars, *Super Lawyers*, 2017-2023

Ones to Watch – Corporate Law, *Best Lawyers*, 2021, 2022

*Who's Who in America*, 2019

## Experience

Traditional IPOs and Uplists:

- Represented Newsmax Inc. (NYSE: NMAX), a television broadcaster and multi-platform content publisher, in its private offering of equity securities and initial public offering for gross proceeds of \$300 million and listing on the New York Stock Exchange
- Represented Legacy Education Inc. (NYSE American: LGCY), an education institution providing career-focused, post-secondary education services, in its initial public offering and listing on NYSE American
- Represented Syra Health Corp. (Nasdaq: SYRA), a healthcare services company, in its initial public offering and listing on Nasdaq
- Represented Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company, in its initial public offering and listing on Nasdaq
- Represented Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biopharmaceutical company, in its initial public offering and listing on Nasdaq
- Represented Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, in its initial public offering and listing on Nasdaq
- Represented Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company, in its initial public offering and listing on Nasdaq
- Represented Immuron Limited (Nasdaq: IMRN), a now commercial and clinical-stage biopharmaceutical company, in its initial public offering and listing on Nasdaq
- Represented Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a now late-stage biopharmaceutical company, in its initial public offering and listing on Nasdaq
- Represented underwriters in an initial public offering and listing on Nasdaq of an architectural design firm that intends to develop an AI-enabled tool to analyze architectural drawings for compliance with local building codes and regulations.
- Represented underwriters in an initial public offering and listing on Nasdaq of an AI-driven visualization solutions company
- Represented underwriters in an initial public offering and listing on Nasdaq of a company in the rideshare industry
- Represented underwriters in an initial public offering of and listing on Nasdaq of a biotechnology company focused on early cancer screening and detection

SPACs:

- Represented A.G.P./Alliance Global Partners in an initial public offering and listing on NYSE American of Ault Disruptive Technologies Corporation (NYSE American: ADRTU)
- Represented A.G.P./Alliance Global Partners in an initial public offering and listing on Nasdaq of Digital Health Acquisition Corp. (Nasdaq: DHACU)

## Other Transactions:

- Represented Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS) on \$575 million follow-on offering
- Represented LKQ Corp. (Nasdaq: LKQ) in a 144A offering of senior unsecured notes in the aggregate principal amount of \$1.4 billion
- Represented Majesco (formerly listed on Nasdaq under the symbol MJCO) in sale to private equity firm for \$729 million

## Articles

- 2025 Top-of-Mind Issues for Life Sciences Companies  
01.31.2025

### Corporate & Securities Law Blog Posts

- "NYSE American Proposes Amendments to Initial Listing Standards," January 16, 2026
- "Section 16(a) Reporting Obligations to Apply to Officers and Directors of Foreign Private Issuers Starting March 18, 2026," January 12, 2026
- "Proposal Granting NASDAQ Discretion To Deny Initial Listings Even If Listings Requirements Are Satisfied," December 30, 2025
- "Navigating Nasdaq and NYSE: Essential Insights for Companies," April 29, 2025
- "Revised Schedule 13g Filing Deadlines Effective as of September 30, 2024 – What You Need to Know," October 1, 2024
- "SEC Adopts Amendments Regarding Insider Trading Plans and Related Disclosures," January 10, 2023
- "SEC Releases Pay Versus Performance Disclosure Requirements For Public Companies," September 19, 2022
- "SEC Proposes Amendments to Schedule 13 Beneficial Ownership Reporting Requirements," February 24, 2022
- "SEC Amends Definitions of "Accelerated Filer" and "Large Accelerated Filer" and Provides Relief to Small Issuers from Auditor Attestation Requirements," March 18, 2020
- "SEC Administrative Proceedings Against Public Companies for Failure to Remediate Material Weaknesses in Internal Control Over Financial Reporting," February 5, 2019
- "Expansion of Regulation A to Reporting Companies: Increased Alternatives Now Available to Public Companies Seeking to Raise Capital or for Mergers and Acquisitions," February 1, 2019
- "The Effects of the SEC Shutdown on the Capital Markets," January 18, 2019
- "SEC Expands the Definition of 'Smaller Reporting Company,'" July 12, 2018

### Cannabis Law Blog Posts

- "Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree?," August 31, 2023
- "FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products," March 9, 2020

## Media Mentions

Sheppard Mullin Advised Newsmax Inc. On Its Private Capital Raise And IPO  
*Mondaq*, 04.04.2025

Majesco's \$12 Million Acquisition of InsPro Technologies  
*Global Legal Chronicle*, 02.24.2020

Genprex's \$8 Million Common Stock Offering  
*Global Legal Chronicle*, 02.22.2020

Aridis Pharmaceuticals' \$26 Million Initial Public Offering  
*Global Legal Chronicle*, 09.25.2018

## Speaking Engagements

Panelist, "How Will the New Nasdaq Rules & Regulatory Changes Affect Which Companies Get Listed and Listed Companies Stay Listed?," Planet Microcap Showcase, Las Vegas, NV, 2025

Panelist, "IPO, SPAC or Reverse Merger and At-The-Market, Registered Direct Offerings or a PIPE," Planet Microcap Showcase, Las Vegas, NV, 2023

Panelist, "Key Considerations for Deal Flow and Corporate Transactions in 2023," South Asian Bar Association of North America, The Next Revolution, Boston, MA, 2023

Speaker, "Effective Tips for Networking" Ms. JD, LaddHerUp, Sonoma, California, 2024 and 2023

## Events

DC Women Lawyers Group Panel & Reception  
10.01.2024

## Memberships

- Board Member, Ms. JD, Mentor
- Leadership Counsel on Legal Diversity

## Practices

Corporate

Capital Markets

Public Company Corporate Governance and Compliance

Mergers and Acquisitions

Canada

International Reach

## Industries

Life Sciences

Healthcare

Cannabis

Food and Beverage

## Education

J.D., California Western School of Law, 2013, *with honors*

B.S., George Mason University, 2010, *cum laude*

## Admissions

Texas

New York

New Jersey

District of Columbia

## Additional Office

New York

## Languages

Hindi

Urdu